Drug
Ibi3011 Group
Ibi3011 Group: highest development phase Phase 2, developed by Innovent Biologics (Suzhou) Co. Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Innovent Biologics (Suzhou) Co. Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| IBI3011 GROUP NCT07842497 | Phase 2 | Acute Gouty Arthritis |
Latest
No recent events.
Follow Ibi3011 Group on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.